CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

Data Compilation
#PharmaFlow

Pipeline Prospector September 2025: Genmab buys Merus for ~US$ 8 billion, Pfizer buys Metsera to enter obesity race

Stock Recap
#PipelineProspector

Asasantin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

74 API Suppliers, 24 USDMF, 8 CEP/COS, 2 JDMF, 2 KDMF, 24 NDC API, 29 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

109 Drugs in Development

109 Drugs in Development

FINISHED DOSAGE FORMULATIONS

638 FDF Dossiers, 117 FDA Orange Book, 271 Europe, 89 Canada, 8 Australia, 32 South Africa, 121 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 356.4MG;30MG;16MG, TABLET;ORAL - 325MG;50MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 325MG;50MG;40MG;30MG, TABLET, DELAYED RELEASE;ORAL - 325MG;40MG, TABLET, DELAYED RELEASE;ORAL - 81MG;40MG, TABLET;ORAL - 250MG;250MG;65MG, CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 325MG;50MG;40MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Minakem, 8 Evonik, 12 Rochem International Inc, 32 SPI Pharma, 30 DKSH, 2 Pharm-RX Chemical, 8 Boai NKY Pharmaceuticals Ltd, 10 Gangwal Healthcare, 15 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Pfanstiehl, 1 Capital Farma, 12 Kirsch Pharma, 4 ACG Worldwide, 15 Actylis, 2 Aeon Procare, 2 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 Ashland, 40 BASF, 1 Bioplus Life Sciences, 5 CD Formulation, 3 Clariant, 15 Corel Pharma Chem, 7 DFE Pharma, 3 Doshion Polyscience, 2 Esteem Industries, 3 Finar, 16 Gangwal Chemicals, 15 Ideal Cures, 5 Ingredion Pharma Solutions, 27 Kerry, 4 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 24 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 5 Pharmatrans-Sanaq, 11 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 47 Roquette, 19 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 5 Vasa Pharmachem, 1 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

113 Fillers, Diluents & Binders, 86 Coating Systems & Additives, 69 Thickeners and Stabilizers, 55 Solubilizers, 49 Direct Compression, 49 Disintegrants & Superdisintegrants, 47 Taste Masking, 46 Controlled & Modified Release, 45 Parenteral, 42 Granulation, 38 Topical, 33 Film Formers & Plasticizers, 31 Lubricants & Glidants, 27 Chewable & Orodispersible Aids, 19 Emulsifying Agents, 18 Rheology Modifiers, 17 Co-Processed Excipients, 14 Surfactant & Foaming Agents, 12 API Stability Enhancers, 9 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 194 News #PharmaBuzz

GLOBAL SALES INFORMATION

19 US Medicaid Prescriptions, 38 Regulatory FDF Prices, 11 Annual Reports

MARKET PLACE

60 APIs, 43 FDF Dossiers

PATENTS & EXCLUSIVITIES

12 US Patents

12 US Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 JP, 12 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
31/10/2025	Seqens	France	NOVACYL SAS	11373	ACETYL SALICYLIC ACID (ASPIRIN USP)	1995-03-06	Active	II	Complete	2013-02-12	2013-01-18
31/10/2025	Seqens	France	NOVACYL SAS	12092	ACETYLSALICYLIC ACID (ASPIRIN USP)	1996-08-01	Active	II	Complete	2013-02-12	2013-01-25

Asasantin

Asasantin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

74 API Suppliers

24 USDMF

8 CEP/COS

2 JDMF

2 KDMF

24 NDC API

29 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

109 Drugs in Development

FINISHED DOSAGE FORMULATIONS

638 FDF Dossiers

117 FDA Orange Book

271 Europe

89 Canada

8 Australia

32 South Africa

121 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 356.4MG;30MG;16MG

TABLET;ORAL - 325MG;50MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 325MG;50MG;40MG;30MG

TABLET, DELAYED RELEASE;ORAL - 325MG;40MG

TABLET, DELAYED RELEASE;ORAL - 81MG;40MG

TABLET;ORAL - 250MG;250MG;65MG

CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 325MG;50MG;40MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI

2 Minakem

8 Evonik

12 Rochem International Inc

32 SPI Pharma

30 DKSH

2 Pharm-RX Chemical

8 Boai NKY Pharmaceuticals Ltd

10 Gangwal Healthcare

15 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

2 Pfanstiehl

1 Capital Farma

12 Kirsch Pharma

4 ACG Worldwide

15 Actylis

2 Aeon Procare

2 Alcedo Pharmachem

10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

4 Ashland

40 BASF

1 Bioplus Life Sciences

5 CD Formulation

3 Clariant

15 Corel Pharma Chem

7 DFE Pharma

3 Doshion Polyscience

2 Esteem Industries

3 Finar

16 Gangwal Chemicals

15 Ideal Cures

5 Ingredion Pharma Solutions

27 Kerry

4 Keval Exports

5 Kima Chemical

6 Lonza Capsugel

24 Microlex e.U

1 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

4 Novo Excipients

5 Pharmatrans-Sanaq

11 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

TABLET;ORAL - 325MG;50MG;40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons